Resources

Fraud, waste, and abuse (FWA) is a national crisis that costs our healthcare system at least $200 billion every year. Even worse, research suggests that only a mere 5% of these losses are recovered.1

MedImpact helps reduce waste and oversupply with flexible auto-refill strategies.

Breaking news of the White House’s consideration of a sweeping executive order that could cut prices on brand-name prescription drugs sold to Medicare and other government programs continues to top this week’s healthcare headlines.

Diabetes spending will continue to increase as new pipeline agents like oral semaglutide enter the market. For now, insulin still dominates the diabetes therapeutic class, accounting for 49% of market share. Newer generation, non-insulin products, like DPP4, SGLT2 or GLP-1s, or combinations that contain them, now make up a combined 50% of market share.

With the potential to change the landscape of diabetes treatment, oral semaglutide ushers in the next generation of diabetes care with its anticipated FDA approval in September.

FDA approves world’s most expensive drug with broad indication to treat rare childhood neuromuscular disease.

The FDA approved a new drug that is a potential game changer for advanced breast cancer patients. Piqray (alpelisib) gained approval on May 24 for treatment of postmenopausal women and men with one of the most commonly mutated genes in advanced or metastatic breast cancer.

When we hear the terms “generic” or “off-brand,” we typically think that the product would be a significantly cheaper alternative than the name brand. Well, when it comes to generic drugs, that’s not always in the case. Here are five facts plan sponsors should know: